Galectin Therapeutics (NASDAQ:GALT) Downgraded to Sell Rating by StockNews.com

Galectin Therapeutics (NASDAQ:GALT) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Friday, August 16th.

Galectin Therapeutics Stock Up 2.4 %

GALT traded up $0.07 during trading on Tuesday, reaching $2.96. The stock had a trading volume of 116,156 shares, compared to its average volume of 145,245. The firm has a market capitalization of $184.34 million, a price-to-earnings ratio of -3.75 and a beta of 0.62. Galectin Therapeutics has a 1-year low of $1.55 and a 1-year high of $4.27. The stock has a 50 day moving average of $2.66 and a two-hundred day moving average of $2.63.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). On average, research analysts forecast that Galectin Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gladstone Institutional Advisory LLC acquired a new stake in shares of Galectin Therapeutics during the third quarter worth approximately $60,000. Retirement Guys Formula LLC increased its holdings in shares of Galectin Therapeutics by 55.1% in the third quarter. Retirement Guys Formula LLC now owns 63,817 shares of the company’s stock valued at $175,000 after purchasing an additional 22,660 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at $227,000. Squarepoint Ops LLC lifted its stake in shares of Galectin Therapeutics by 75.4% in the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock valued at $190,000 after purchasing an additional 36,139 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Galectin Therapeutics in the 2nd quarter valued at $43,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.